Semaglutide (GLP-1)

Reimbursable Weight Management

Medical Weight Loss

Reimbursable Semaglutide (GLP-1) Program

Semaglutide (GLP-1) is a medication used to treat Type 2 diabetes and aid in long-term weight management. For medical providers contemplating integrating Semaglutide (GLP-1) into their clinic programs for patients, Diabetes Testing Centers™ (DTC) provides a holistic and innovative solutions to tackle weight loss difficulties while addressing hunger management. Other than lowering blood sugar levels and reducing weight, studies show that GLP-1 agonists may have other potential benefits, like: Lowering blood pressure. Improving lipid disorders. Medical providers should administer comprehensive consultations, meticulously evaluating each patient's medical background and performing evidence-based assessments to customize treatment plans. These assessments aid in optimizing medical weight loss and offer invaluable insights into potential diabetes-related conditions, guiding proactive management strategies for improved patient outcomes.

Over 2/3 of adults in the U.S. are either overweight or have obesity. 

Key takeaways


GLP-1s are becoming increasingly popular and may change how obesity is perceived and handled. It is believed that this shift could lead to doctors treating multiple co-morbidities associated with obesity by prioritizing weight-centric treatment. This could mark a significant change in the way obesity and Type 2 diabetes is managed. 

U.S. Obesity Market is Expanding Rapidly  

Is testing required for this program?

Yes, assessments are necessary beyond regular lab tests while you're taking any (GLP-1) medication. The required assessments include hemoglobin A1c blood sugar - which can help determine if the medication is covered by insurance or not, cardiovascular disease is the #1 killer of men and women, and cognitive function enables early detection of cognitive decline and improves adherence and engagement while on a weight loss regimen. These assessments should also be repeated periodically to monitor your body's response to the medication.


Insurance Coverage May be Possible

Medications like Ozempic and other GLP-1 may be covered by health insurance for individuals with type 2 diabetes. The first way to determine possible coverage is by having patients get their A1c's tested for diabetes and if positive, coverage eligibility. Patients should consult their healthcare providers for guidance. Using an A1cNOW+ fingerstick test can determine that fact in 5-minutes at the point of care before the patient leaves the clinic.


Exploring the Benefits of Semaglutide (GLP-1)

Clinical studies conducted over the years have consistently demonstrated that Semaglutide (GLP-1), a medication that works by mimicking the effects of the hormone GLP-1, is superior to other treatments when it comes to promoting weight loss and controlling appetite, ultimately leading to significant weight reduction. Since it was granted approval by the FDA, Semaglutide (GLP-1) has quickly become a widely prescribed medication, offering numerous additional benefits such as reduced risk of heart disease, lower blood pressure, improved mobility, enhanced mental clarity, better sleep, and increased self-esteem to those who take it regularly.


Importance of Pre- and Post-Therapy Assessments

To fully understand the benefits of Semaglutide therapy, it's crucial to conduct assessments to establish baseline health metrics for each patient before and after its introduction. Clinical studies have highlighted Semaglutide's superior efficacy in weight loss, offering improved appetite control and significant reductions in weight. Since FDA approval, Semaglutide has been widely prescribed, providing additional benefits, including enhanced cardiovascular health, lower blood pressure, improved mobility, mental clarity, better sleep, and increased self-esteem. These benefits underscore the importance of thorough baseline assessments to track patients' progress throughout their treatment journey. 


Diabetes Testing Centers™ (DTC) provides reimbursable assessment for pre- and post- Semaglutide (GLP-1) therapy for clinics and their patients for the following:


A1c Results in 5-minutes

Digital Cognitive Assessment

Heart Attack & Stroke Assessment

Unlock the Potential of Semaglutide: A Game-Changer in Weight Loss

Semaglutide, originally approved as a Type 2 diabetes treatment in 2005 with Byetta, the first FDA Approved GLP-1 and has grown the class to others like Ozempic, Wegovy, Monjauro, effectively stabilizes glycemic levels by curbing appetite and promoting glycemic balance in the body. Complemented with a healthy diet and regular exercise, it offers remarkable benefits in weight loss management.


Understanding the Mechanism of Semaglutide

As a peptide GLP-1 receptor agonist, Semaglutide interacts with the body's hunger-regulating hormone, GLP-1, inducing feelings of fullness and triggering insulin secretion to normalize blood sugar levels. It also slows gastric emptying, facilitating weight loss.


GLP-1 Can Reduce Risks of Cardiovascular Death (Heart Attack and Stroke)

Navigating the Semaglutide Treatment

Semaglutide injections, typically administered weekly, bimonthly or monthly and are painless and well-tolerated by patients when administered by medical providers. After the initial treatment, patients self-administer injections at home and return for follow-up visits, ensuring optimal results.


Understanding Potential Side Effects of Semaglutide

While most patients experience no issues, potential side effects include nausea, vomiting, diarrhea, indigestion, and constipation, which are typically transient and manageable.


Recommendations

Diabetes Testing Centers™ offer quick and efficient methods, such as point-of-care A1c tests, to determine diabetes status within minutes. These tests and additional screenings provide valuable insights into glycemic control and potential complications, guiding informed decisions for diagnosis and treatment plans. Follow-up visits ensure effective management, potentially reversing complications associated with weight loss. Additionally, we simplify the process by helping healthcare providers access Semaglutide (GLP-1) w/B12 and Tirzepitide (GIP) w/B12 in your state for resale to patients, ensuring that this life-changing treatment is affordable and accessible to everyone.


To learn more about how our program can benefit your practice and explore our array of diabetes-related products and services, we invite medical providers to contact Diabetes Testing Centers™ (DTC) today. Contact us before your competitor does and embark on a journey toward better patient care and improved practice efficiency in diabetes management and weight loss.

Simply Better